Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Hence why the opportunity to buy at 5 year lows
Which I did
Thanks for the words of wisdom as ever....on shares you don't hold nor intend to
Very odd
Most did not miss this from the Interims:
"FUNDING UPDATE
The Company has been investigating an equity raise with institutional and other investors. Having regard to the unfavourable conditions in small-cap equity markets, the Board has concluded that it will not be possible to complete an equity raise at the current time. As at 30 November 2022, having recently received the R&D tax credit for FY 2022, the Company has cash of £10.0 million, and through deferring certain expenditure on proprietary programmes and other longer term development plans, the cash runway will be extended until at least the start of the fourth calendar quarter of 2023. This is not expected to compromise the Company's ability to sign commercial exosome collaborations which upon completion should extend the runway until at least 2024."
Which is why the share price crashed at the beginning of the month. And, Directors have not seen fit to buy any shares since the news was announced, even though they are 'cheap'.
most importantly, it ended the half with a gross cash position of £10.5 million, enough to fund operations until circa this time next year. For context, this is almost double RENE’s current market cap.
ReNeuron has signed a Supplemental Terms Agreement with Fosun Pharm for the tech transfer of its platforms into China, and while it has received £320,000 thus far, it expects a further £680,000 over the next two years. Notably, the FTSE AIM company believes that there is potential ‘to receive up to £5 million over the medium to long term, with further potential milestone payments of up to £74 million linked to the main agreement signed in 2019
I am in the same boat Allenby. Slowly watching my investment disappear.
I this their 'Last chance saloon'.. ?
They have some deals pipelined and the Market Cap looks less than their current cash. I've averaged down this week using a dividend from elsewhere so that in my head at least, I'm not averaging down with anymore investing capital.
Hi Phill I have 60K shares and in the same sinking boat as you. Been here since 2017 and was taken in by all the hype by the BOD and others on this board . Have learnt a expensive lesson over the 5 years but still hope for Reneuron to come good over the next 12 months but as I have said before the CFO does not have much of a hand to play to get a good deal over the next 12 months for the company or its long suffering shareholders, but we can all hope she can pull it off.
The term ‘topping up’ is sometimes used by proponents of this stock, to reflect buys in the hundreds. Phil if you’re sitting on 200k I wish you well as I do others who similarly ‘put their money where their mouth is’. Good luck and a very good Christmas and new year.
New CEO Catherine does look very experience and knows her knowledge on the subject matter.
lots of news to come.
Could get interesting as Sp dropped from 30p due to seller
GLA and Dyor
#RENE
CEO was at #AstraZeneca making the Covid vaccine
Now she can repeat her success on @ReNeuronPLC then £10M Mcap could become £70M Mcap
watch the video below
https://t.co/m7iJSbzFtH
wow 770% to level with the valuation
#RENE #RENUERON currently 10.5p https://t.co/yk57d5kykA
We continue to value ReNeuron at £44.2m or 77p per share. https://t.co/zXndwhRAqn
Cash £10m vs Mcap £5.8m
way oversold!!
Commercial deal coming!!
as per rns
ReNeuron's CustomExTM platform is the only platform that offers this ability to customise the exosome cell type for a partners' need and the payload / target cell of their choice, while offering a scalable and repeatable manufacturing process due to its patented conditional immortalisation technology. This technology was enabled through the Company's earlier work in producing GMP stem cells approved by the FDA and MHRA for the clinic from which the Company's exosomes are now produced.
Fosun Pharma continues to develop CTX in stroke disability in China following the out-licensing agreement signed with ReNeuron in April 2019. In July 2022, ReNeuron announced that it had negotiated and signed a supplemental terms agreement with Fosun. As a result, the Group expects to receive approximately £1 million over the 24 month period from signing the agreement (including the £320,000 upfront payment received in January 2022) in relation to the initial supply of CTX cell bank vials and services provided to undertake the technology transfer, with up to a further £5 million receivable by the Group over the medium to longer term for the continued provision of CTX cell bank vials to enable manufacture by Fosun Pharma and with further potential milestone payments of up to £74m linked to the main agreement signed in 2019.
Fosun Pharma is expanding its cell therapy portfolio to stem cell platforms and ReNeuron CTX is one of the starting programmes. A dedicated Fosun Pharma team has been established for the technology transfer into China and the construction of a 20,000 square foot GMP facility to manufacture CTX is underway. The signing of this Supplemental Terms Agreement underscores Fosun Pharma's continued commitment to the CTX stroke disability programme.
The collaboration with Fosun Pharma continues on track and the Group continues to progress out-licensing opportunities for the CTX programme in other geographies.
Following the cessation of the hRPC programme earlier in the year, work has been ongoing to complete the data package that can be made available to potential interested parties. This data package is expected to be completed in Q4 2022. There has been some early interest in this programme and the Group will accelerate efforts to progress this once the data package is available.
Outlook
With the executive team now in place, the key focus over the coming period for myself and the rest for the team will be data generation and collaboration deals to further extend the cash runway.
We are targeting to announce several larger scale exosome collaborations from existing / new partners and to develop further collaboration agreements with our iPSC platform. We also plan to accelerate the number of partnering opportunities in the 'hopper' through a greater focus on marketing of the advantages of the CustomExTM platform. This, I believe, will lead to further success for the Company over the longer term.
I'm still licking my wounds. Nothing constructive to add at this point - remain confident that they will secure a licencing deal before the lights go off, for what its worth.
Got 200k shares now, badly underwater obviously, but if they deliver a licencing deal (not sure where any of these rumors are coming from - suspect nobody knows anything and the pump and dump brigade have perhaps taken an interest in us), then obviously the upside could be absolutely ridiculous from these levels. We live in hope.
seller took this down from 30p
looks like seller is out next week.
£26k buy the printed
should be interested next week
With all this noise, where’s Phil?
wow 770% to level with the valuation
#RENE #RENUERON currently 10.5p https://t.co/yk57d5kykA
We continue to value ReNeuron at £44.2m or 77p per share. https://t.co/zXndwhRAqn
wow 770% to level with the valuation
#RENE #RENUERON currently 10.5p https://t.co/yk57d5kykA
We continue to value ReNeuron at £44.2m or 77p per share. https://t.co/zXndwhRAqn
Commercial deal coming!!
as per rns
ReNeuron's CustomExTM platform is the only platform that offers this ability to customise the exosome cell type for a partners' need and the payload / target cell of their choice, while offering a scalable and repeatable manufacturing process due to its patented conditional immortalisation technology. This technology was enabled through the Company's earlier work in producing GMP stem cells approved by the FDA and MHRA for the clinic from which the Company's exosomes are now produced.
Cash £10M
no Debt
Mcap £5.8M
wow!!!
need 72% to level with cash position!!
GLA and Dyor before others find out!!!
Cash £10M
no Debt
Mcap £5.8M
wow what need 72% to level with cash position!!
GLA and Dyor before others find out!!!
Course you will Laura haha
Group ended the period with cash, cash equivalents and bank deposits of £10.5 million and with our cash runway being extended until at least the start of the fourth calendar quarter 2023 and the right team now in place, the Company will look to build on these foundations and sign new longer-term commercial partnerships to further extend the cash runway and therefore deliver value commensurate with what our CustomExTM platform can offer in the field of targeted drug delivery
From what I can see, the major shareholder is completely out and RENE is at three year lows with cash until 2023/24
I will be buying my first shares in RENE tomorrow
Terry what is a TWD ?
As there’s generally little substance to anything posted on this board, certainly anything I post, it seems a little unfair to single out DD, particularly during this Christmas season. Let’s hope ‘ 23 is better but as is often quoted, do your own research.